Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study.

IF 3.1 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Ayelet David, Orit Stolar, Matitiahu Berkovitch, Elkana Kohn, Ariela Hazan, Danel Waissengreen, Eynat Gal
{"title":"Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study.","authors":"Ayelet David, Orit Stolar, Matitiahu Berkovitch, Elkana Kohn, Ariela Hazan, Danel Waissengreen, Eynat Gal","doi":"10.1089/can.2024.0001","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> The literature supports the benefits of medical cannabis for core and comorbid symptoms in autistic individuals and anxiety-related symptoms in individuals without autism. However, no study has specifically investigated how cannabidiol (CBD)-rich cannabis affects anxiety subtypes in autistic children or its relationship with restricted and repetitive behaviors and interests (RRBI). Understanding the effects of CBD-rich cannabis treatment on anxiety subtypes and RRBI could offer more precise treatment approaches to managing anxiety symptoms and reducing RRBI frequency in autistic children. <b>Objectives:</b> To examine (1) the impact of CBD-rich cannabis treatment on autistic children's (1a) anxiety levels and subtypes and (1 b) RRBI and subtypes and (2) whether changes in anxiety explain changes in RRBI following cannabis treatment. <b>Method:</b> In this open-label study, we analyzed data from 65 autistic children (5-12 years) who had participated in research on the effects of CBD-rich cannabis on children with autism. Their parents completed the Repetitive Behavior Scale-revised to assess the frequency and severity of six subgroups of their children's recurrent behaviors and the Screen for Child Anxiety-Related Emotional Disorders for symptoms related to five types of anxiety disorders. They completed these assessments at three time points: (T1) before treatment, (T2) after 3 months, and (T3) after 6 months of treatment. <b>Results:</b> The results indicated reduced RRBI and symptoms related to various anxiety subtypes in autistic children following 6 months of CBD-rich cannabis treatment. Specifically, we observed significant differences in the autistic children's overall anxiety and in some anxiety subtypes (i.e., general, social, panic, and separation anxieties). Significant improvements were observed in RRBI, including the total score, and specifically in compulsive, ritualistic, and sameness behaviors. Our findings revealed that reduced anxiety, particularly within the panic- and separation-related subtypes, predicted a subsequent decrease in RRBI, specifically sameness behaviors, following cannabis treatment. <b>Conclusions:</b> The findings of the cannabis treatment's potential benefits for alleviating anxiety symptoms, leading to reduced RRBI, may provide evidence for the meaningful relationship between these variables and for the potential benefits of cannabis treatment for autistic children. We strongly recommend further double-blind, placebo-controlled studies using standardized assessments to validate these findings.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cannabis and Cannabinoid Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/can.2024.0001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The literature supports the benefits of medical cannabis for core and comorbid symptoms in autistic individuals and anxiety-related symptoms in individuals without autism. However, no study has specifically investigated how cannabidiol (CBD)-rich cannabis affects anxiety subtypes in autistic children or its relationship with restricted and repetitive behaviors and interests (RRBI). Understanding the effects of CBD-rich cannabis treatment on anxiety subtypes and RRBI could offer more precise treatment approaches to managing anxiety symptoms and reducing RRBI frequency in autistic children. Objectives: To examine (1) the impact of CBD-rich cannabis treatment on autistic children's (1a) anxiety levels and subtypes and (1 b) RRBI and subtypes and (2) whether changes in anxiety explain changes in RRBI following cannabis treatment. Method: In this open-label study, we analyzed data from 65 autistic children (5-12 years) who had participated in research on the effects of CBD-rich cannabis on children with autism. Their parents completed the Repetitive Behavior Scale-revised to assess the frequency and severity of six subgroups of their children's recurrent behaviors and the Screen for Child Anxiety-Related Emotional Disorders for symptoms related to five types of anxiety disorders. They completed these assessments at three time points: (T1) before treatment, (T2) after 3 months, and (T3) after 6 months of treatment. Results: The results indicated reduced RRBI and symptoms related to various anxiety subtypes in autistic children following 6 months of CBD-rich cannabis treatment. Specifically, we observed significant differences in the autistic children's overall anxiety and in some anxiety subtypes (i.e., general, social, panic, and separation anxieties). Significant improvements were observed in RRBI, including the total score, and specifically in compulsive, ritualistic, and sameness behaviors. Our findings revealed that reduced anxiety, particularly within the panic- and separation-related subtypes, predicted a subsequent decrease in RRBI, specifically sameness behaviors, following cannabis treatment. Conclusions: The findings of the cannabis treatment's potential benefits for alleviating anxiety symptoms, leading to reduced RRBI, may provide evidence for the meaningful relationship between these variables and for the potential benefits of cannabis treatment for autistic children. We strongly recommend further double-blind, placebo-controlled studies using standardized assessments to validate these findings.

医用大麻治疗自闭症儿童对焦虑、受限和重复行为及兴趣的影响:一项开放标签研究
背景:文献支持医用大麻对自闭症患者的核心症状和合并症状以及非自闭症患者的焦虑相关症状有好处。然而,还没有研究专门探讨富含大麻二酚(CBD)的大麻如何影响自闭症儿童的焦虑亚型,以及大麻与限制性和重复性行为和兴趣(RRBI)之间的关系。了解富含 CBD 的大麻治疗对焦虑亚型和 RRBI 的影响,可为控制自闭症儿童的焦虑症状和减少 RRBI 频率提供更精确的治疗方法。研究目的研究(1)富含 CBD 的大麻治疗对自闭症儿童(1a)焦虑水平和亚型以及(1b)RRBI 和亚型的影响;(2)焦虑的变化是否可以解释大麻治疗后 RRBI 的变化。研究方法:在这项开放标签研究中,我们分析了 65 名自闭症儿童(5-12 岁)的数据,这些儿童曾参与富含 CBD 的大麻对自闭症儿童的影响研究。他们的父母填写了重复行为量表(修订版),以评估其子女的六组重复行为的频率和严重程度,并填写了儿童焦虑相关情绪障碍筛查表,以评估与五种焦虑症相关的症状。他们在三个时间点完成了这些评估:治疗前(T1)、治疗 3 个月后(T2)和治疗 6 个月后(T3)。结果显示结果表明,经过 6 个月富含 CBD 的大麻治疗后,自闭症儿童的 RRBI 和与各种焦虑亚型相关的症状均有所减轻。具体而言,我们观察到自闭症儿童的总体焦虑和某些焦虑亚型(即一般焦虑、社交焦虑、恐慌焦虑和分离焦虑)存在显著差异。在 RRBI(包括总分),特别是强迫行为、仪式行为和同一性行为方面,我们观察到了显著的改善。我们的研究结果表明,焦虑的减少,尤其是恐慌和分离相关亚型焦虑的减少,预示着大麻治疗后 RRBI,尤其是同一性行为的减少。结论:大麻治疗对缓解焦虑症状的潜在益处可导致 RRBI 的减少,这些研究结果可证明这些变量之间存在有意义的关系,并证明大麻治疗对自闭症儿童的潜在益处。我们强烈建议使用标准化评估进一步开展双盲安慰剂对照研究,以验证这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cannabis and Cannabinoid Research
Cannabis and Cannabinoid Research PHARMACOLOGY & PHARMACY-
CiteScore
6.80
自引率
7.90%
发文量
164
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信